Skip to content

EBITDA margin at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
27.9%-2.8pp
Opko Health logo
Opko HealthOPK
-1.9%-0.9pp
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-2,749.9%-808pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
2.2%+1.1pp
ALN
Alnylam PharmaceuticalsALNY
18.8%+16.9pp
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-622.2%-198pp

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.07B+111%
Enterprise value$1.07B+103%
P/S13.5×-1.3×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Calculated from MeiraGTx Holdings plc’s reported figures.

Based on trailing twelve months.

The official record: MeiraGTx Holdings plc’s 10-Q, filed November 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about MeiraGTx Holdings plc's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MeiraGTx Holdings plc's EBITDA margin?
MeiraGTx Holdings plc (MGTX) reported EBITDA margin of -552.3% in Q3 2025.
How has MeiraGTx Holdings plc's EBITDA margin changed year-over-year?
MeiraGTx Holdings plc's EBITDA margin increased by 52.7% year-over-year, from -1,168.9% to -552.3%.
What is the long-term trend for MeiraGTx Holdings plc's EBITDA margin?
Over 3 years (2020 to 2024), MeiraGTx Holdings plc's EBITDA margin has grown at a 6.6% compound annual growth rate (CAGR), from -375.1% to -454.9%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.